Appraising Current Safety and Efficacy Data for PARP Inhibitors in Ovarian Cancer: Best Practices in Treatment and Adverse Event Management
Expert faculty for this 30-minute webinar will include a gynecologic oncologist and a nurse. This webinar will provide an overview of the latest data in PARP inhibitor therapy for the treatment of ovarian cancer in patients with different biomarker profiles and at different stages of the disease. Recent clinical data and rationale for PARP inhibitor use in the first-line maintenance setting will be discussed. Faculty will share unique toxicity profiles among the different PARP inhibitors and best practices in monitoring, preventing, and treating adverse events that may arise with therapy.
Gynecologic oncologists, medical oncologists, gynecologists, and other members of the healthcare team who manage patients with ovarian cancer.
- Explore the most recent clinical trial data for the use of PARP inhibitors in ovarian cancer, including national guidelines and the rationale for their use in the first‐line maintenance setting.
- Analyze the safety profiles of different PARP inhibitors and best practices in the monitoring, prevention, and management of these adverse events.
Supported through an independent educational grant from GlaxoSmithKline.
Beth Y. Karlan, MD
Professor and Vice Chair of Women’s Health Research
Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Director, Cancer Population Genetics
UCLA-Jonsson Comprehensive Cancer Center
Los Angeles, CA
Jennifer Filipi, MSN, NP
Center for Gynecologic Oncology
Massachusetts General Hospital
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Beth Y. Karlan, MD–has disclosed that she is an advisor or consultant to Bluestar Genomics, F. Hoffmann-LaRoche, Ltd., FUJIFILM Pharmaceuticals USA, Grail, Inc., and Mercy BioAnalytics, Inc. She also receives research support from Aravive, Inc., Immunogen, Incyte Corporation, Merck & Co., Inc., Mersana Therapeutics, and Zentalis Pharmaceuticals.
Jennifer Filipi, MSN, NP–has no relevant financial relationships to disclose in relation to the content of this activity.
Pamela Peters, MD–has disclosed that she receives grant funding from Foundation for Women's Cancer.
Susan H. Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Tina L. Trieu, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™ per webinar. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Upon completion of a CE Request Form, statements of credit for physicians will be issued.
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation